Perhaps this slightly higher rate is attributable to development of noninvasive radiological methods.22 Even though a radiological diagnosis of glioma can be made with high certainty, the molecular status needed to determine the appropriate treatment strategy is not yet possible to deduce from radiology alone.23,24 Further work with PET shows promising results for noninvasive O[6]-methylguanine-DNA methyltransferase (MGMT) status, which would be much needed in patients with non-resectable high-grade gliomas to avoid the surgical risk associated with biopsy.25 This evidence concerns the gene MGMT and central nervous system cancer.